BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: However, in 2014, this finding was challenged by Chinese researchers with the conclusion that the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with CML.20